Iron stores and hemoglobin synthesis

"Iron stores" refers to the body's reserve of bioavailable iron—primarily stored as ferritin in the liver and reticuloendothelial system—which is essential for numerous biological functions. "Hemoglobin synthesis" is the process by which developing erythroid cells incorporate heme-bound iron into globin chains to form functional hemoglobin molecules. This process requires coordinated regulation of dietary absorption, cellular import via transferrin receptors and DMT1 transporters, mitochondrial import through mitoferrins, enzymatic conversion steps including those catalyzed by ALAS2 and ferrochelatase, and tight systemic control via hormones such as hepcidin. Disruption at any step can lead to clinical disorders such as anemia or systemic toxicity due to excess free iron. Both "iron stores" and "hemoglobin synthesis" describe complex physiological pathways rather than discrete molecular targets; thus they are not considered canonical therapeutic targets but rather represent interconnected networks involving multiple proteins that may individually serve as drug targets[1][2][3][5].

Other names

Iron metabolismHemoglobin biosynthesisIron homeostasisHeme synthesis

For drugs targeting these processes: - Increase dietary or parenteral iron to replenish body stores and support erythropoiesis. - Stimulate erythroid progenitor proliferation/differentiation to increase hemoglobin production. - Chelate excess iron to prevent toxicity.